Aptorum Group

Aptorum Group Net Margin

Delisted·Sep 22, 2026

The Net Profit Margin of Aptorum Group (APM) as of Oct 29, 2026 is -654.88 %. In the previous year, Net Profit Margin was -756.17 % — a change of -13.40% (higher).

Net Margin

-654.88 %

YoY

-13.40%

Last updated:

Net Profit Margin of Aptorum Group is 2023 -654.88 % . Net Profit Margin of Aptorum Group was 2022 -756.17 % . It decreases by -13.40% higher compared to the previous year.

Aptorum Group's net margin stands at -654.9%, up from -3,491.8% several years earlier.

The Aptorum Group Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-3,868.04 USD
Jan 1, 2019
-3,491.81 USD
Jan 1, 2020
775.31 USD
Jan 1, 2021
-1,624.38 USD
Jan 1, 2022
-756.17 USD
Jan 1, 2023
-654.88 USD
The Aptorum Group Net Margin history
YEARNet MarginYoY
-654.88 %-13.40%
-756.17 %-53.45%
-1,624.38 %-309.51%
775.31 %-122.20%
-3,491.81 %-9.73%
-3,868.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptorum Group Stock analysis

What does Aptorum Group do? Aptorum Group Ltd. develops pharmaceutical products targeting unmet medical needs in infectious diseases, cancers, metabolic disorders, and neurology. The company leverages drug discovery platforms to screen approved drug molecules and microbiome-based research for metabolic treatments. It commercializes therapeutic assets through systematic screening and microbiome research, focusing on diseases like infectious conditions, cancer, and metabolic disorders. The company also pursues projects in gastroenterology, women’s health, and surgical robotics, alongside natural supplements for menopausal symptoms. Aptorum Group Ltd. generates revenue by advancing therapeutic and diagnostic projects across multiple disease areas. Its products include treatments for infectious diseases, cancers, and metabolic conditions, developed through drug discovery platforms and microbiome research. The company targets healthcare providers, pharmaceutical partners, and patients seeking innovative treatments for conditions with limited existing options. Segments include infectious disease therapies, cancer treatments, metabolic disorder solutions, and women’s health products. The company’s revenue streams come from the development and commercialization of therapeutic assets. It focuses on drug discovery through systematic screening of approved molecules and microbiome-based research for metabolic diseases. Projects in neurology, gastroenterology, and women’s health contribute to its product portfolio, alongside surgical robotics and natural supplements for menopausal symptoms. Aptorum Group Ltd. serves medical professionals and patients requiring novel treatments for underserved disease areas. Aptorum Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptorum Group stock

Net Profit Margin of Aptorum Group is -654.88 % in 2023.

Net Profit Margin of Aptorum Group changed from -756.17 % to -654.88 %, representing a -13.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Aptorum Group since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Aptorum Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Aptorum Group

All Key Metrics — Aptorum Group